ResearcherMie UniversityActive in the last 2 years
Toru Shinkai
Matched on ORCID iD 0000-0002-9474-1541; OpenAlex author ID A5080993088. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 6
- Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
- Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
- Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
- Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
- Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Con… Co-author DOI 10.1097/mpa.0000000000001902↗
- [I. The Efficacy of Preoperative Adjuvant Treatment for Pancreatic Ductal Adenocarcinoma Based on the Resectability Criteria according to JPS 7th]. Co-author PMID 29066676↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yasuhiro Murata · 6 shared papers, 2017–2025 · strength 0.88
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Aoi Hayasaki · 6 shared papers, 2017–2025 · strength 0.88
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Masashi Kishiwada · 6 shared papers, 2017–2025 · strength 0.88
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Kazuyuki Gyoten · 5 shared papers, 2021–2025 · strength 0.80
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Shugo Mizuno · 5 shared papers, 2021–2025 · strength 0.80
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Naohisa Kuriyama · 5 shared papers, 2021–2025 · strength 0.80
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Takahiro Ito · 4 shared papers, 2022–2025 · strength 0.69
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Benson Kaluba · 4 shared papers, 2022–2025 · strength 0.69
- Paper Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. DOI 10.1016/j.suronc.2025.102269↗
- Paper Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resec… DOI 10.1097/mpa.0000000000002440↗
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Shuji Isaji · 4 shared papers, 2017–2023 · strength 0.48
- Paper Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic d… DOI 10.1016/j.hpb.2023.06.015↗
- Paper Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with l… DOI 10.21203/rs.3.rs-2229927/v1↗
- Paper Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized P… DOI 10.1097/mpa.0000000000001902↗
- Miki Usui · 1 shared paper, 2025 · strength 0.20
- Masatoshi Watanabe · 1 shared paper, 2025 · strength 0.20
- Hiroyuki Sakurai · 1 shared paper, 2021 · strength 0.11
- Hiroyuki Kato · 1 shared paper, 2017 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.